Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Eli Lilly · Phase 1/2 · Active, not recruiting · Enrollment 190

NCT06700538

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Part 1: ARO-INHBEn/rn/rn/rn/r
Part 1: Placebon/rn/rn/rn/r
Part 2: ARO-INHBE + Tirzepatiden/rn/rn/rn/r
Part 2: Placebo + Tirzepatiden/rn/rn/rn/r
Part 3: ARO-INHBEn/rn/rn/rn/r
Part 3: Placebon/rn/rn/rn/r
Part 3: ARO-INHBE + Tirzepatiden/rn/rn/rn/r
Part 3: Placebo + Tirzepatiden/rn/rn/rn/r

Not shown

  • Part 1: ARO-INHBE: endpoint not reported
  • Part 1: Placebo: endpoint not reported
  • Part 2: ARO-INHBE + Tirzepatide: endpoint not reported
  • Part 2: Placebo + Tirzepatide: endpoint not reported
  • Part 3: ARO-INHBE: endpoint not reported
  • Part 3: Placebo: endpoint not reported
  • Part 3: ARO-INHBE + Tirzepatide: endpoint not reported
  • Part 3: Placebo + Tirzepatide: endpoint not reported